Deeter Investments LLP’s Cytokinetics CYTK Stock Holding History

Deeter Investments LLP’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$6.27M	Buy	+98,739	New	+$6.14M	1.34%	25

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deeter Investments LLP's CYTK Position: Q4 2025 in Review

Deeter Investments LLP opened a new position in Cytokinetics (CYTK) in Q4 2025: 98,739 shares worth $6.27M. The stake represents 1.34% of the portfolio and ranks #25 among its holdings.

431 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Deeter Investments LLP held 98,739 shares of Cytokinetics worth $6.27M as of Q4 2025.
Cytokinetics was a new Deeter Investments LLP position in Q4 2025.
Cytokinetics made up 1.34% of Deeter Investments LLP's portfolio in Q4 2025, its #25 holding.
431 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Deeter Investments LLP's 13F filing for Q4 2025, filed 28 Aug 2026.